But, at least in the venture capital world, funding for companies
focused on tackling
heart disease, respiratory disease, and other mass population conditions — i.e., those that afflict millions
upon millions of people — has dropped sharply in the last decade.
While the diagnostic criteria of POTS
focuses on the abnormal
heart rate increase
upon standing, sufferers usually present with a wide set of symptoms beyond blood pressure and rate irregularities.